In support of our previous findings, we observed worse outcomes in several clinical categories, including disease-free survival, AJCC tumor stages and nodes pathology, and lymphovascular and vascular invasion, in patients with higher PHLDB2 expression (Figs. 1, 2). Here, PHLDB2 is linked to neoplasm.